MYD88 and diffuse large B-cell lymphoma: Since DLBCL with JAK2/PD-L2 amplification had less frequency of MYD88 L265P mutation, our study separated DLBCL patients into three subgroups: DLBCL with JAK2/PD-L2 amplification (DLBCL_JAK2/PD-L2_amp), DLBCL with MYD88 L265P mutation (DLBCL_MYD88_L265P), and DLBCL without JAK2/PD-L2 amplification nor MYD88_L265P mutation (DLBCL_others) (Fig. 2a).